Status:
UNKNOWN
Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders
Lead Sponsor:
University of Calgary
Collaborating Sponsors:
Heart and Stroke Foundation of Canada
Conditions:
Heart Failure, Congestive
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Approximately 40% of resynchronization therapy recipients do not appear to clearly benefit. These patients are termed 'non-responders'. This study will assess whether a heart ultrasound (echo) techniq...
Detailed Description
Background: Despite advances in pharmacotherapy, patients with heart failure (HF) are at high risk for death and hospitalization. Over 25% of patients with systolic HF have dyssynchronous ventricular ...
Eligibility Criteria
Inclusion
- non-response to CRT as indicated,
- stable doses of ACE I / ARB and beta-blocker for ≥ 2 months, \&
- controlled heart rate if in atrial fibrillation.
Exclusion
- inadequate images to assess torsion
- no significant augmentation in torsion with optimization
- unable or unwilling to provide informed consent,
- medical condition other than HF likely to cause death within 6 months,
- cardiac transplant planned,
- myocardial infarction or revascularization since CRT implant.
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2017
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00867984
Start Date
March 1 2009
End Date
January 1 2017
Last Update
November 24 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Calgary
Calgary, Alberta, Canada, T2N 4N1